Kim Brewer1, 2, Drew DeBay3, Kerry Lake3, Iulia Dude3, 4, Genevieve Weir1, Marc Mansour1, Chris Bowen, 23
1Immunovaccine Inc., Halifax, NS, Canada; 2School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada; 3Institute for Biodiagnostics (Atlantic), National Research Council of Canada, Halifax, NS, Canada; 4Physics, University of Waterloo, Waterloo, ON, Canada
Immunotherapies are aimed at potentiating the bodys immune response. DepoVaxTM is an immunotherapy vaccine that encapsulates the tumor-associated antigens in liposomes, which are then suspended in oil. The oil acts as an adjuvant, which improves the potency of the peptides and aids in eliciting a strong immune response. This work investigated whether an increase in the draining lymph node (LN) volume (right inguinal LN) could be used as a biomarker for successful vaccination (i.e. successful tumor suppression). This was done by performing longitudinal LN volumetry using MRI to evaluate changes using receiver operating characteristic (ROC) curves.